Drug Name |
Cabotegravir |
Drug ID |
BADD_D02537 |
Description |
Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, [rilpivirine].[A227668,L31188,L31193] Early research into cabotegravir showed it had lower oral bioavailability than [dolutegravir].[A227668] The devlopment of cabotegravir was later developed to create a long acting monthly intramuscular injection.[A227668,L31193]
Cabotegravir was granted FDA approval on 21 January 2021.[L31198] |
Indications and Usage |
Oral cabotegravir is indicated in combination with rilpivirine for the short term treatment of HIV-1 in virologically suppressed adults with no history of treatment failure to assess tolerability of cabotegravir or who have missed an injected dose of cabotegravir.[L31188] Intramuscular extended-release cabotegravir is indicated in combination with rilpivirine as a complete regimen for virologically suppressed adults with no history of treatment failure.[L31193] The intramuscular form is meant to replace their current antiretroviral treatment.[L31193] |
Marketing Status |
approved; investigational |
ATC Code |
J05AJ04 |
DrugBank ID |
DB11751
|
KEGG ID |
D10548
|
MeSH ID |
C584914
|
PubChem ID |
54713659
|
TTD Drug ID |
D08LDB
|
NDC Product Code |
49702-264; 52482-017 |
UNII |
HMH0132Z1Q
|
Synonyms |
cabotegravir | (3S,11aR)-N-((2,6-difluoropyridin-3-yl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide | cabotegravir sodium | GSK-1265744B | sodium (3S,11aR)-8-(((2,4-difluorophenyl)methyl)carbamoyl)-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo(3,2-a)pyrido(1,2-d)pyrazin-6-olate | S-265744B | GSK1265744B | Vocabria | cabotegravir extended-release injectable suspension | Apretude | GSK1265744 | GSK744 | S-265744 | GSK-1265744A | GSK-1265744 | GSK1265744A | N-((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide |